koustav_sarkar.jpg

Dr. Koustav Sarkar

Ph.D

Research Assistant Professor


Dr. Koustav Sarkar is working as a Research Assistant Professor in SRM Research Institute and associated with the Department of Biotechnology at SRM University, since April 2016. His research focuses on explicating the molecular underpinnings of immune dysregulation and cancer immunology immunotherapy.

Research Contribution:

Dr. Sarkar has been involved in research over the last fourteen years (including a Ph.D. and three Post-Docs) and made several important contributions to the development of advanced science and technology. He was involved in understanding the molecular mechanisms of the development of human immune responses in health & disease. He has already published 25 high-impact scientific publications in internationally reputed journals with citation indices 437 and h-index 13. He is also co-author of four book chapters and fourteen conference proceedings. During Ph.D., Dr. Sarkar has developed a process for isolating glycoprotein(s) from neem leaf, which has immunomodulatory and cancer preventive functions. One patent (Patent Number: 259434; Grant Date: 12-Mar-2014) has been granted for this invention. He found out that the neem leaf glycoprotein helped to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage & dendritic cell mediated antigen presentation to T and B cells and the induction of type 1 protective immunity. To study the intricate molecular mechanisms involved in the type 1 protective immunity, Dr. Sarkar moved to USA. Research from his US laboratory was essential in revealing for the first time a novel nuclear function for a well known cytoskeleton structure associated protein, Wiskott Aldrich Syndrome Protein (WASp) in the transcriptional regulation of T helper cell 1 (Th1)-differentiation through its effect on epigenetic modifications at the T-BET gene-promoter locus. Since that time, Dr. Sarkar has been actively involved in further understanding how WASp associates with and regulates protein pathways and gene networks that control development of protective type-1 immunity.

Academic Profile:

Education:


Institution and Location

Degree

   Year

Banaras Hindu University, Varanasi, India

MSc

2002

Jadavpur University, Kolkata, India

PhD

2009

Professional Career:

August 14, 2002 – Present

  • Research Assistant Professor (SRM University, Kattankulathur, Tamil Nadu – 603203, India) [April 01, 2016 – Present]  
  • Post-Doctoral Research Scholar (University of Iowa Children’s Hospital, Iowa City, USA) [June 30, 2013 – March 25, 2016]
  • Post-Doctoral Associate (Children’s Hospital of Pittsburgh, Pittsburgh, USA) [Sept 15, 2009 – June29, 2013] 
  • Post-Doctoral Research Fellow (Massachusetts General Hospital, Harvard University, Boston, USA) [Feb 02, 2009 - Sept 14, 2009] 
  • Senior Research Fellow (Indian Council of Medical Research) [Dec 1, 2005 - Jan 30, 2009]
  • Junior Research Fellow (Department of Science and Technology, Govt. of India) [Mar 01, 2003 - Jul 24, 2005] 
  • Project Fellow (University Grants Commission, India) [Aug 14, 2002 - Feb 28, 2003]

Awards:

  1. DST-SERB Early Career Research Award – A grant of ~Rs. 45 lakhs
  2. American Association of Immunologists (AAI) 2015 Trainee Abstract Award

Achievements: 

Citations of the Postdoctoral work (Apart from Published Papers)

  • One of the works was chosen for perspective of Science Translational Medicine 2, 37ps31, 2010: “Alternative control: Whatʼs WASp doing in the nucleus?” by Teitell, M. A.
  • One of our experimental figures was chosen for the ONLINE COVER of Science Translational Medicine 23 June 2010 as “A Closer Look at Wiskott-Aldrich syndrome” [http://stm.sciencemag.org/content/2/37.cover-expansion].
  • The research work was also cited in The Money Times as “Study identifies disease protein” [http://www.themoneytimes.com/20100623/study-identifies-disease-protein-id- 10118440.html]. Eureka Alert described our findings as “The Sting of WASp in Immune Disorders”[http://www.eurekalert.org/multimedia/pub/23428.php].
  • The work was also narrated in Ecoworld as “Study identifies disease protein” [http://www.ecoworld.com/?s=Study+identifies+disease+protein&x=0&y=0&=Go]

Citations of the Doctoral works (Apart from Published Papers)

Fellowships:

  • Post-Doctoral Research Scholarship from National Institutes of Health National Institute of Allergy and Infectious Diseases, USA funded two R01 grants (#AI07356 and #AI084957) (September 15, 2009 – March 25, 2016)
  • Post-Doctoral Research Fellowship from MGPO, USA funded grant (February 2, 2009 – September 14, 2009)
  • Senior Research Fellowship from ICMR, India sponsored project (December 1, 2005 – January 30, 2009)
  • Junior Research Fellowship from DST, India sponsored project (March 1, 2003 – July 27, 2005)
  • Project Fellowship from UGC, India sponsored project (August 14, 2002 – February 28, 2003)

Membership of professional bodies:

  • Member of The American Association of Immunologists
  • Life Member of Indian Science Congress
  • Life Member of Indian Association for Cancer Research
  • Life Member of Indian Immunology Society

Invited Talks:

  • Sarkar K. Sumoylation switches Wiskott Aldrich Syndrome Protein (WASp) from a transcriptional activator to a repressor. Invited talk at CSIR-Central Drug Research Institute, Lucknow, UP, India on November 27, 2015.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF-Complexes in T cells by WAS Mutations Distinguishes X-linked Thrombocytopenia from Wiskott-Aldrich Syndrome. Invited for oral presentation at 4th Annual Retreat of Center for Immunology and Immune-based Diseases, Iowa City, IA, USA on August 20, 2015.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Nucleosomal Remodeling Defects at Gene Promoters Underlie Cross-Phenotype Effects in X-linked Thrombocytopenia/Wiskott-Aldrich Syndrome. Invited for oral presentation at Block symposium of American Association of Immunologists (AAI) Annual Meeting 2015, New Orleans, LA, USA, May 8-12, 2015.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF-Complexes in T cells by WAS Mutations Distinguishes X-linked Thrombocytopenia from Wiskott-Aldrich Syndrome. Invited for oral presentation on Pediatric Research Day symposium 2015, Iowa City, IA, USA.

Journal Reviewer:

  • Reviewer of “Journal of Oncology” by Hindwai Publishing Corporation

1. Immune Dysregulation:

 I have an interest in understanding the molecular mechanisms of the development of human immune responses in health and disease. We have chosen to use the genetic disease model of Wiskott-Aldrich syndrome (WAS) to determine the partners and pathways of WAS protein (WASp) participation in the regulation of CD4 T helper cell differentiation and the development of T cell adaptive immunity. Human WAS is an X-linked genetic disease manifesting in severe immune deficiency, autoimmunity, thrombocytopenia, and lymphoid cancers in young boys. In order to clarify WASp’s role in immune regulation in health, and immune dysregulation in WAS, our laboratory has taken the complementary approach of investigating the functions of WASp from both vantage points, i.e. cytoplasm and nucleus. Research from our laboratory was essential in revealing for the first time a novel nuclear function for WASp in the transcriptional regulation of Th1-differentiation through its effect on epigenetic modifications at the T-BET gene-promoter locus (Science Translational Medicine, 2(37):37ra44, 2010). Epigenetic mechanisms are essential for normal development and maintenance of tissue-specific gene expression patterns in mammals. Disruption of epigenetic processes can lead to altered gene function and malignant cellular transformation. Global changes in the epigenetic landscape are a hallmark of malignancy. The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. It has already been well documented by our lab that Wiskott-Aldrich syndrome protein (WASp) plays a crucial role in the epigenetic regulation of T helper (Th) cell differentiation and the development of T cell adaptive immunity (Journal of Immunology, 193(1):150-160, 2014). Our lab also showed that some mutations or lack of WASp results into severe immunodeficiency and lymphoid malignancy in Wiskott-Aldrich syndrome (Blood, 124(23):3409-3419, 2014; Blood, 126, 1670-1682, 2015). Any kind of malignancy leads into genomic instability. Our lab is now focusing on the molecular mechanisms involved in this kind of genomic instability. We have already seen that in the absence of WASp, human and murine Th-cells are unable to activate transcription of Th1-network genes for protective immunity. Thus the epigenetic regulation of Th cell differentiation linked to malignancies offers us an appealing avenue for targeted therapeutic intervention of multifaceted WASp through different types of molecular mechanisms. Pictorial illustrations of some key relevant findings from our lab are as follows:

 

Sarkar et al. 2015; Blood, 126: 1097-2015   

 

 

    Sarkar et al. 2014; Blood, 124: 3409-3419

2. Cancer Immunology Immunotherapy:

I am also interested in cancer immunotherapy that works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer more powerfully, to offer longer-term protection against the disease, to come with fewer side effects, and to benefit more patients with more cancer types. Main focus of my past work was on presentation of tumor antigens to T- and B-cells through macrophages and dendritic cells using immunomodulators. We discovered a novel immunomodulator, Neem Leaf Glycoprotein (NLGP) for which we got a patent also. Optimum antigen presentation and co-stimulation by NLGP plays major role in immune mediated tumor growth restriction. By up-regulating expression of co-stimulatory molecule, CD28 and CD154 on T cells, and CD40, CD80, CD86 on APCs with simultaneous downregulation of CTLA4, NLGP stabilizes APC-T cell synapse, and in turn generates cancer specific CTLs. Using NLGP we showed creation of type-1 antitumor immunity related with significant tumor growth restriction in prophylactic as well as therapeutic settings. We also developed a monoclonal antibody against neem leaf glycoprotein recognizes carcinoembryonic antigen (CEA) and we found out the ability of this monoclonal antibody to restrict CEA expressing tumor growth. We want to elucidate the detailed molecular mechanisms of NLGP in tumor growth restriction. In addition to NLGP, we also evaluated the immunomodulatory effects of IFNa2b in head and neck squamous cell carcinoma patients. IFNα2b augments suppressed immune functions in tobacco related head and neck squamous cell carcinoma patients. IFNα2b stimulates the release of IFNγ and this IFNγ differentially regulates T and NK cell mediated tumor cell cytotoxicity. A pilot study on tongue squamous cell carcinoma patients suggested IFNα2b was efficient to improve immunity in those patients receiving standard chemotherapy and radiotherapy. Based on these results a phase III, randomized, open level, superiority study was proposed on tongue squamous cell carcinoma patients to be treated with IFNα2b along with concomitant chemoradiotherapy. One of our preliminary studies showed that IFNα2b augmented immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients. We hope our all the studies will definitely add up a significant contribution to the immunotherapeutic approaches for cancer treatment.

 

Leader

  • Dr. Koustav Sarkar

Postdoctoral Fellows

  • To be updated

Research Fellows

  • Srividya G (SRM University JRF)
  • Mathuravalli K (DST-SERB-ECRA project JRF)

Project Assistants

  • To be updated

  • International Journal Papers: 25
  • Conference Papers: 14
  • Patent: 01 (Granted)
  • Book Chapters: 04

Original Articles:

Published

  • Ghosh T, Barik S, Bhuniya A, Dhar J, Ghosh S, Sarkar M, Guha I, Sarkar K, Chakrabarti P, Saha B, Storkus WJ, Baral R, Bose A. Tumor-associated mesenchymal stem cells inhibit naïve T cell expansion by blocking cysteine export from dendritic cells. Int J Cancer, 139, 2068-2081, 2016. Impact factor: 5.531.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. SUMOylation-disrupting WAS Mutation Converts WASp from a Transcriptional Activator to a Repressor of NF-κB Response Genes in T cells. Blood, 126, 1670-1682, 2015. Impact factor: 11.841. ISSN: 0006-4971. Cited by related articles: 1.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF-Complexes in T cells by WAS Mutations Distinguishes X-linked Thrombocytopenia from Wiskott-Aldrich Syndrome. Blood, 124, 3409-3419, 2014. Impact factor: 11.841. ISSN: 0006-4971. Cited by related articles: 4.
  • Sadhukhan S*, Sarkar K*, Taylor M, Candotti F, Vyas YM. Nuclear Role of WASp in Gene Transcription is Uncoupled from its ARP2/3-Dependent Cytoplasmic Role in Actin Polymerization. *Both authors contributed equally to this paper. J Immunol, 193, 150-160, 2014. Impact factor: 5.36. ISSN: 0022-1767. Cited by related articles: 12.
  • Das A, Barik S, Banerjee S, Bose A, Sarkar K, Biswas J, Baral R, Pal S. A monoclonal antibody against neem leaf glycoprotein recognizes carcinoembryonic antigen (CEA) and restricts CEA expressing tumor growth. J Immunother, 37, 394-406, 2014. Impact factor: 3.712. ISSN: 1524-9557. Cited by related articles: 2.
  • Mallick A, Barik S, Ghosh S, Roy S, Sarkar K, Bose A, Baral R. Immunotherapeutic targeting of established sarcoma in Swiss mice by tumor-derived antigen-pulsed NLGP matured dendritic cells is CD8(+) T-cell dependent. Immunotherapy, 6, 821-831, 2014. Impact factor: 2.44. ISSN: 1750-743X. Cited by related articles: 2.
  • Mallick A, Barik S, Goswami KK, Banerjee S, Ghosh S, Sarkar K, Bose A, Baral R. Neem leaf glycoprotein activates CD8+ T cells to promote therapeutic anti-tumor immunity inhibiting the growth  of mouse sarcoma. PLoS One, 8, e47434, 2013. Impact factor: 3.534. ISSN: 1932-6203. Cited by related articles: 21.
  • Mallick A, Ghosh S, Banerjee S, Majumder S, Das A, Mondal B, Barik S, Goswami KK, Pal S, Laskar S, Sarkar K, Bose A, Baral R. Neem Leaf Glycoprotein is Nontoxic to Physiological Functions of Swiss Mice and Sprague Dawley Rats: Histological, Biochemical and Immunological Perspectives. Int Immunopharmacol, 15, 73-83, 2013. Impact factor: 2.659. ISSN: 1567-5769. Cited by related articles: 12.
  • Mukherjee KK, Bose A, Ghosh D, Sarkar K, Goswami S, Pal S, Biswas J, Baral R. IFNa2b augments immune responses of cisplatin+5-fluorouracil treated tongue squamous cell carcinoma patients - a preliminary study. Indian J Med Res, 135, 57- 62, 2012. Impact factor: 2.061. ISSN: 0971-5916. Cited by related articles: 5.
  • Chakraborty K, Bose A, Goswami KK, Mukherjee KK, Ghosh D, Goswami S, Chakraborty T, Sarkar K, Pal S, Bhowmick A, Biswas J, Baral R. Dysregulated CC receptor/ligand in monocytes/macrophages from tongue squamous cell carcinoma patients is partially rectified by interferon α-2b. Hum Immunol, 73, 38-47, 2012. Impact Factor: 2.298. ISSN: 0198-8859. Cited by related articles: 4.
  • Roy S, Goswami S, Bose A, Goswami KK, Sarkar K, Chakraborty K, Chakraborty T, Pal S, Haldar A, Basu P, Biswas J, Baral R. Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon α2b (IFNα2b) in cervical cancer. Translational  Research, 158, 200-213, 2011. Impact Factor: 4.557. ISSN: 1931-5244. Cited by related articles: 5.
  • Chakraborty T, Bose A, Barik S, Goswami KK, Banerjee S, Goswami S, Ghosh D, Roy S, Chakraborty K, Sarkar K, Baral R. Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth. Immunotherapy, 3, 949-969, 2011. Impact Factor: 2.393. ISSN: 1750-743X. Cited by related articles: 13.
  • Chakraborty K, Bose A, Chakraborty T, Sarkar K, Goswami S, Pal S, Baral R. Restoration of dysregulated CC chemokine signaling for monocyte/macrophage chemotaxis in head and neck squamous cell carcinoma patients by neem leaf glycoprotein maximizes tumor cell cytotoxicity. Cell Mol Immunol (Nature Publising Group), 7, 396-408, 2010. Impact Factor: 5.193. ISSN: 1672-7681. Cited by related articles: 20.
  • Taylor MD, Sadhukhan S, Kottangada P, Ramgopal A, Sarkar K, DʼSilva S, Selvakumar A, Candotti F, Vyas YM. Nuclear Role of WASp in the Pathogenesis of Dysregulated TH1-Immunity in Human Wiskott-AldrichSyndrome. Sci Transl Med (Science AAAS), 2, 37ra44, 2010. Impact Factor: 15.843. ISSN: 1946-6242. Cited by related articles: 61.
  • Sarkar K, Goswami S, Roy S, Mallick A, Chakraborty K, Bose A, Baral R. Neem leaf glycoprotein enhances carcinoembryonic antigen presentation of dendritic cells to T and B cells for induction of antitumor immunity by allowing generation of immune effector/memory response. Int Immunopharmacol, 10, 865-874, 2010. Impact Factor: 2.659. ISSN: 1567-5769. Cited by related articles: 22.
  • Goswami S, Bose A, Sarkar K, Roy S,  Chakraborty T, Baral R. Neem leaf glycoprotein matures myeloid derived dendritic cells and optimizes anti-tumor T cell  functions. Vaccine, 28, 1241-1252, 2010. Impact Factor: 3.492. ISSN: 0264-410X. Cited by related articles: 31.
  • Gupta M, Sarkar K, Baral R, Laskar S. Some chemical investigations of Amoora rohituka seed proteins. Food Chemistry, 119, 1057-1062, 2010. Impact Factor: 4.052. ISSN: 0308-8146. Cited by related articles: 9.
  • Sarkar K, Bose A, Haque E, Chakraborty K, Chakraborty T, Goswami S, Ghosh D, Baral R. Induction of type 1 cytokines during neem leaf glycoprotein assisted carcinoembryonic antigen vaccination is associated with nitric oxide production. Int Immunopharmacol, 9, 753-760, 2009. Impact Factor: 2.659. ISSN: 1567-5769. Cited by related articles: 12.
  • Bose A, Chakraborty K, Sarkar K, Chakraborty T, Goswami S, Pal S, Baral R. Neem leaf glycoprotein induces perforin mediated tumor cell killing by T and NK cells through differential regulation of IFNgamma signaling. J Immunother, 32, 42-53, 2009. Impact Factor: 3.712. ISSN: 1524-9557. Cited by related articles: 26.
  • Bose A, Chakraborty K, Sarkar K, Goswami S, Haque E, Chakraborty T, Ghosh D, Roy S, Laskar S, Baral R. Neem leaf glycoprotein directs T-bet associated type 1 immune commitment. Human Immunol, 70, 6-15, 2009. Impact Factor: 2.298. ISSN: 0198-8859. Cited by related articles: 25.
  • Sarkar K, Bose A, Chakraborty K, Haque E, Ghosh D, Goswami S, Chakraborty T, Laskar S, Baral R. Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific antitumor immune responses utilizing macrophage mediated antigen presentation. Vaccine, 25, 4352-4362, 2008. Impact Factor: 3.492. ISSN: 0264-410X. Cited by related articles: 30.
  • Chakraborty K, Bose A, Pal S, Sarkar K, Goswami S, Chattopadhyay U, Baral R. Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int Immunopharmacol, 8, 330-340, 2008. Impact Factor: 2.659. ISSN: 1567-5769. Cited by related articles: 34.
  • Sarkar K, Bose A, Laskar S, Chaudhuri SK, Dey S, Roychoudhuri PK, Baral R. Antibody response against neem leaf preparation recognizes carcinoembryonic antigen. Int Immunopharmacol, 7, 306-312, 2007. Impact Factor: 2.659. ISSN: 1096- 9861. Cited by related articles: 26.
  • Sakharkar AJ, Singru PS, Sarkar K, Subhedar NK. Neuropeptide Y in the forebrain of the adult male cichlid fish Oreochromis mossambicus: distribution, effects of castration and testosterone replacement. J Comp Neurol, 489, 148-165. Impact Factor: 3.508. ISSN: 1096-9861. Cited by related articles: 47.
  • Das SK and Sarkar K. A new method for isolation of leukocytes from the peripheral blood of amphibians [Bufo himalayanus, (Gunther)] and study of their surface morphology by scanning electron microscopy. Indian J Exp Biol, 43, 488-492, 2005. Impact Factor: 1.165. ISSN: 0975-1009. Cited by related articles: 2.

Patent:

  • Baral RN, Laskar S, Bose A, Sarkar K, Process for isolating glycoprotein from neem leaf and its characterization to define the immunomodulatory and cancer preventive functions of this glycoprotein. Patent Number: 259434; Indian Patent Application Number: 429/KOL/2007; Publication Date: 14-Mar-2014; Grant Date: 12-Mar-2014.

Book Chapters:

  •  Bose A, Goswami S, Roy S, Sarkar K, Chakraborty K, Chakraborty T, Haque E, Laskar S, Baral R. Immunotherapeutic Targeting of Multiple Dysregulated Immune Functions in Cancer by Neem Leaf Glycoprotein. In: Natural Products: Research Reviews (Ed. V. K. Gupta) Vol 1, Chap 2, Daya Publishing House, 2012. ISBN 13 9788170357759; ISBN 10 8170357756
  • Baral RN, Sarkar K, Mandal-Ghosh I, Bose A. Neem leaf glycoprotein as a new vaccine adjuvant for cancer immunotherapy. In: “Comprehensive Bioactive Natural Products; Immune-modulation & Vaccine Adjuvants” (Ed. V. K. Gupta), Vol 5, Chap 2, Studium Press LLC, USA, 2010, pp. 21-45. ISBN-10 1933699558.
  • Bose A, Chakraborty K, Sarkar K, Goswami S, Chakraborty T, Haque E, Ghosh D, Mandal- Ghosh I, Pal S, Laskar S, Chattopadhyay U and Baral RN. Cancer Immunoediting: Prefessional Editorship by Neem leaf glycoprotein. In: “Treatments of Advanced Stage Cancers: current status and emerging frontiers” (Ed. G. P. Talwar & O. P. Sood) by Narosa Publishing House Pvt. Ltd, India, 2009, pp 148-152. ISBN 10: 8173199329; ISBN 13: 9788173199325.
  • Chakraborty T, Bose A, Chakraborty K, Sarkar K, Goswami S, Haque E, Ghosh D, Mandal- Ghosh I, Pal S, Laskar S and Baral RN. Suppression of Suppressors: Neem leaf glycoprotein Guided Crosstalk Between Regulatory T cells and T cells/NK Cells/ Macrophages in Cancer. In: “Treatments of Advanced Stage Cancers: current status and emerging frontiers” (Ed. G.P. Talwar & O. P. Sood) by Narosa Publishing House Pvt. Ltd, India, 2009, pp 153-157. ISBN 10: 8173199329; ISBN 13: 9788173199325.

Conference Abstracts:

  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF-Complexes in T cells by WAS Mutations Distinguishes X-linked Thrombocytopenia from Wiskott-Aldrich Syndrome. Selected for both poster and oral presentation(s) at 4th Annual Retreat of Center for Immunology and Immune-based Diseases, Iowa City, IA, USA, August 20, 2015.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Nucleosomal Remodeling Defects at Gene Promoters Underlie Cross-Phenotype Effects in X-linked Thrombocytopenia/Wiskott-Aldrich Syndrome. Selected for both poster and oral presentation(s) at Block symposium of American Association of Immunologists (AAI) Annual Meeting 2015, New Orleans, LA, USA, May 8-12, 2015.
  • Sarkar K, Sadhukhan S, Han SS, Vyas YM. Disruption of hSWI/SNF-Complexes in T cells by WAS Mutations Distinguishes X-linked Thrombocytopenia from Wiskott-Aldrich Syndrome. Selected for both poster and oral presentation(s) on Pediatric Research Day symposium 2015, Iowa City, IA, USA.
  • Sadhukhan S*, Sarkar K*, Matthew D Taylor, Yatin M Vyas. Identifying the divergent roles of WASp in Nuclear and Cytoplasmic compartments during T helper 1 (Th1) cell differentiation. 2nd Annual Rangos Research Symposium 2012, Childrenʼs Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA. *These authors contributed equally to this work.
  • Bose A, Goswami S, Roy S, Sarkar K, Chakraborty K, Chakraborty T, Haque E, Laskar S, Baral R. Immunotherapeutic targeting of multiple dysregulated immune functions in cancer by neem leaf glycoprotein. World Congress on Biotechnology, Hyderabad, India, March 21-23, 2011.
  • Baral R, Bose A, Sarkar K, Chakraborty K, Goswami S, Chakrabraty T, Roy S, Haque E, Ghosh D, Pal S, Laskar S. Neem leaf glycoprotein breaks T cell anergy by polarizing optimum immune requirement for maximum restriction in tumor growth. 100th Annual Meeting of American Association for Cancer Research, Colorado Convention Center, Denver, Colorado, USA, April 18-22, 2009.
  • Sarkar K, Bose A, Ghosh D, Goswami S, Chakraborty K, Chakraborty T, Kundu P, Laskar S and Baral RN, Purified neem leaf glycoprotein regulates signaling between innate, humoral and cellular immune functions in murine tumor system: An insight on tumor vaccine development. 2nd International Symposium on Translational Research on Natural products and Cancer, Lonavala, Mumbai, India, December 9-12, 2007.
  • Goswami S, Bose A, Sarkar K, Chakraborty K, Chakraborty T, Laskar S and Baral RN, Neem leaf glycoprotein directed maturation of dendritic cells helps them to act as a direct killer or promotes killer instinct of cytotoxic T cells to tumors. 2nd International Symposium on Translational Research on Natural products and Cancer, Lonavala, Mumbai, India, December 9-12, 2007.
  • Ghosh D, Sarkar K, Bose A, Goswami S, Kundu P, Laskar S, and Baral RN, Neem leaf glycoprotein is the active ingredient of neem leaf, responsible for murine tumor growth restriction by immunoprophylaxis. Symposium on “Recent Trends in Cancer Research and Treatment”, Golden Jubilee Celebration, Chittaranjan National Cancer Institute, Kolkata, India, November 1-3, 2007.
  • Chakraborty T, Bose A, Chakraborty K, Goswami S, Sarkar K, Pal S and Baral RN, Neem leaf derived glycoprotein inhibits suppressor functions of regulatory T cells to induce tumor cell cytotoxicity by T cells, NK cells and macrophages. Symposium on “Recent Trends in Cancer Research and Treatment”, Golden Jubilee Celebration, Chittaranjan National Cancer Institute, Kolkata, India, November 1-3, 2007.
  • Ghosh D, Sarkar K, Bose A, Haque E and Baral RN, Cancer chemotherapy induced murine leukopenia can be reduced by pretreatment with neem leaf preparation. “CME 2007: Scientific meet on haemato-oncology”, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India, September 8-9, 2007.
  • Goswami S, Bose A, Sarkar K, Chakraborty K, Chakraborty T, Laskar S and Baral RN, Dendritic Cell based vaccine: Role of neem leaf derived glycoprotein in its maturation. “CME 2007: Scientific meet on haemato-oncology”, Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India, September 8-9, 2007.
  • Goswami S, Bose A, Sarkar K, Chakraborty K, Chakraborty T, Laskar S and Baral RN, Neem leaf derived glycoprotein matures human monocytic dendritic cells in Th1 bias: A comparison with lipopolysaccharide. Sympo Soc Bio Chem, Viswa-Bharati, Shantiniketan, India, August 3-5, 2007.
  • Sarkar K, Haque E, Bose A, Mandal I and Baral RN, Enhancement of carcinoembryonic antigen presenting function of murine peritoneal macrophages by neem leaf preparation: Relevance with antibody generation, Th1 cytokine signaling and nitric oxide production. 26 th Ann Conv Ind Assoc Cancer Res, Institute of Life Sciences and  Imgenex, India, Bhubaneswar, India, January 17-19, 2007.

2016 Odd Semester [July – November]

  • M. Tech. Biotechnology: III Semester
  • Course Name: Stem Cell Technology

2017 Even Semester [January – May]

  • B. Tech. Biotechnology: VI Semester
  • Course Name: Stem Cell Biology
  • B. Tech. Biotechnology: IV Semester
  • Course Name: Immunology

Postdoctoral Positions

  • Will be updated soon

PhD

  • Will be updated soon

Project Assistants

  • Will be updated soon

Contact:

Dr. Koustav Sarkar
DST-SERB Early Career Researcher
Research Assistant Professor
Research Institute and Department of Biotechnology
SRM University, Kattankulathur-603203, Tamilnadu, India
Email: koustavsarkar.m@ktr.srmuniv.ac.in
Phone: 044-2471 7908